- Home
- IPW vs ADAP Comparison
IPW vs ADAP Comparison
Compare IPW & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPW
- ADAP
- Stock Information
- Founded
- IPW 2018
- ADAP 2008
- Country
- IPW United States
- ADAP United Kingdom
- Employees
- IPW N/A
- ADAP N/A
- Industry
- IPW Catalog/Specialty Distribution
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- IPW Consumer Discretionary
- ADAP Health Care
- Exchange
- IPW Nasdaq
- ADAP Nasdaq
- Market Cap
- IPW 19.8M
- ADAP 21.3M
- IPO Year
- IPW 2021
- ADAP 2015
- Fundamental
- Price
- IPW $0.53
- ADAP $0.04
- Analyst Decision
- IPW
- ADAP Hold
- Analyst Count
- IPW 0
- ADAP 6
- Target Price
- IPW N/A
- ADAP $1.02
- AVG Volume (30 Days)
- IPW 125.4K
- ADAP 61.2M
- Earning Date
- IPW 09-19-2025
- ADAP 08-13-2025
- Dividend Yield
- IPW N/A
- ADAP N/A
- EPS Growth
- IPW N/A
- ADAP N/A
- EPS
- IPW N/A
- ADAP N/A
- Revenue
- IPW $74,105,251.00
- ADAP $65,084,999.00
- Revenue This Year
- IPW $8.31
- ADAP N/A
- Revenue Next Year
- IPW $77.15
- ADAP $52.35
- P/E Ratio
- IPW N/A
- ADAP N/A
- Revenue Growth
- IPW N/A
- ADAP N/A
- 52 Week Low
- IPW $0.41
- ADAP $0.04
- 52 Week High
- IPW $2.36
- ADAP $1.19
- Technical
- Relative Strength Index (RSI)
- IPW 44.04
- ADAP 28.72
- Support Level
- IPW $0.46
- ADAP $0.06
- Resistance Level
- IPW $0.54
- ADAP $0.07
- Average True Range (ATR)
- IPW 0.06
- ADAP 0.01
- MACD
- IPW 0.00
- ADAP 0.00
- Stochastic Oscillator
- IPW 47.11
- ADAP 1.47
About IPW iPower Inc.
iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.